Notice of publication: Explanatory notes for drug establishments on the preparation of a site master file (GUI-0005)

Drug Establishment Licensing Bulletin 194 April 10, 2026

On this page

About the publication

On April 10, 2026, Health Canada published the following guidance document:

This is adapted from the following Pharmaceutical Inspection Cooperation Scheme document:

As an active participating PIC/S member, Health Canada is aligning with international harmonisation of compliance standards by adapting these annexes.

This guide is an annex to the following Health Canada guidance document:

These guides are to be read together. They will help you understand and comply with Part C, Division 2, of the Food and Drug Regulations (FDRs), which is about good manufacturing practices.

Overview of key changes

This revised guidance document contains no content changes. Formatting and language changes were updated to make the document clearer and align with current industry practices.

We made changes to the following:

How to contact us

If you have any questions, we invite you to contact the Health Product Inspection and Licensing Division (HPIL) of the Regulatory Operations and Enforcement Branch (ROEB).

Email: drug.gmp.questions-bpf.medicaments@hc-sc.gc.ca

Page details

2026-04-10